![](https://media.asiaone.com/sites/default/files/styles/a1_600x316/public/original_images/Aug2024/pr-newswire_500_4_180.jpg?h=7de12b8a&itok=8nxk3YFQ)
Innovent and SanegeneBio Announce First Participant Dosed in a Phase 1 Clinical Trial of IBI3016 (AGT siRNA)
SAN FRANSCISO and SUZHOU, China, Aug. 2, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the …